Several presentations at the UEG Week international conference
back up Theradiag’s work and Lisa Tracker’s benefits
Croissy-Beaubourg and Montpellier, October 29, 2014 – THERADIAG (ISIN: FR0004197747, Ticker: ALTER, PEA-PME eligible), a company specializing in theranostics and in vitro diagnostics, observed strong interest among gastroenterologists in biotherapy monitoring for chronic inflammatory bowel diseases (IBD) at the United European Gastroenterology Week international conference in Vienna (Austria).
During the event, Theradiag’s experts were invited to present various results from their studies:
Prof. Xavier Roblin gave a presentation of the results of a study using a clear and complete algorithm for choosing a therapeutic strategy based on drug dosage and anti-drug antibodies in IBD patients with a loss of response to Adalimumab (Humira®). This study confirms that dosages can be used to optimize therapy, to change it for another anti-TNFα or to change it for another therapeutic class. The use of dosages also provides additional information concerning the chances of success following the adjustment of the therapy.
The data has been published in The American Journal of Gastroenterology, a journal that is part of the Nature group.
In a second presentation, experts reported on the benefits of consecutive dosage in refining therapeutic decision-making concerning IBD patients treated with Infliximab (Remicade®). Patients may develop anti-drug antibodies either permanently or temporarily. The dosage results can be used to predict a loss of response to the therapy, anticipate it and adapt the therapy accordingly even before relapse has occurred in a patient.
“Monitoring tests, such as the the Lisa Tracker kits, represent vital tools enabling us to predict the chances of success of a therapy and adapt it in the event of loss of response”, comments Prof. Xavier Roblin.
“The results of these studies provide further clinical evidence supporting the use of monitoring tests. The strong interest shown by experts and practitioners in these various presentations confirm the importance of the medical needs. Firstly, these tests enable doctors to adapt and optimize use of biodrugs and, secondly, they can have a very significant impact on the cost of drugs, leading to substantial savings in health spending”, adds Michel Finance, Theradiag’s Chief Executive Officer.
Capitalizing on its expertise in the distribution, development and manufacturing of in vitro diagnostic tests, Theradiag innovates and develops theranostics tests (combining treatment and diagnosis) that measure the efficiency of biotherapies in the treatment of autoimmune diseases, cancer and AIDS. Theradiag notably markets the Lisa-Tracker range (CE marked), which is a comprehensive multiparameter theranostics solution for patients with autoimmune diseases treated with biotherapies. With its subsidiary Prestizia, Theradiag is developing new biomarkers based on microRNAs for the diagnosis and monitoring of HIV/AIDS and rectal cancer. Theradiag is thus participating in the development of “customized treatment”, which favors the individualization of treatments, the evaluation of their efficacy and the prevention of drug resistance. The Company is based in Marne-la-Vallée, near Paris, and in Montpellier, and has over 65 employees.
For further information about Theradiag, please visit our website: www.theradiag.com
|Investor Relations||Financial communications /||Press|
|Nathalie Trepo||Investor relations||Caroline Carmagnol /|
|Phone: +33 1 64 62 10 12||Valentine Brouchot /||Valentine Boivin|
|email@example.com||Pierre Laurent||Phone: +33 6 64 18 99 59|
|Phone: +33 1 44 71 94 firstname.lastname@example.org|